Jacobs & Co. CA Buys 2,460 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Jacobs & Co. CA increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,166 shares of the medical research company’s stock after acquiring an additional 2,460 shares during the period. Jacobs & Co. CA’s holdings in Thermo Fisher Scientific were worth $7,519,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Halpern Financial Inc. boosted its holdings in Thermo Fisher Scientific by 307.7% in the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $33,000. Live Oak Investment Partners acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $36,000. Tyler Stone Wealth Management acquired a new stake in Thermo Fisher Scientific in the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $38,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,277 shares of company stock valued at $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.9 %

NYSE:TMO opened at $579.37 on Thursday. The company’s 50-day simple moving average is $564.32 and its 200-day simple moving average is $519.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock has a market capitalization of $220.92 billion, a P/E ratio of 37.50, a P/E/G ratio of 2.39 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same period in the previous year, the business posted $5.40 EPS. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Royal Bank of Canada upped their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price target on the stock. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Robert W. Baird restated an “outperform” rating and set a $670.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Finally, HSBC began coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $599.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.